Background The Cardiac Safety Research Consortium (CSRC) provides both "learning" and blinded "testing" digital electrocardiographic (ECG) data sets from thorough QT (TQT) studies annotated for submission to the US Food and Drug Administration (FDA) to developers of ECG analysis technologies. This article reports the first results from a blinded testing data set that examines developer reanalysis of original sponsor-reported core laboratory data.
The QT interval as recorded by a surface electrocardiogram (ECG) is a measure of the time from the onset of ventricular depolarization to the end of ventricular repolarization, with QT prolongation generally interpreted as a surrogate marker for possible delayed myocardial repolarization. Drug-induced QT prolongation is associated with an increased risk of potentially fatal ventricular arrhythmias such as torsades de pointes. To minimize the incidence of drug-induced torsades de pointes, the US Food and Drug Administration (FDA), through the International Committee on Harmonization E14 guidance document, recommends that all novel drugs with systemic exposure submitted for marketing approval should be first evaluated to assess cardiac risk in target patient populations. 1 The thorough QT (TQT) study is a rigorous evaluation of the effect of a novel drug on cardiac repolarization as measured by the QT interval and heart rate-corrected QT interval (QTc) duration, with mean QTc prolongation of 5 ms as the threshold for regulatory concern. 2, 3 A TQT study requires precise interval duration measurements (IDMs) on as many as 30,000 manually or semiautomated measured ECG measurements per study, each of which is commonly overread for confirmation by an experienced cardiologist. [4] [5] [6] [7] [8] Availability of a fully or virtually automated algorithm to measure IDMs accurately may accelerate timelines and reduce variability of ECG measurements with consequent reduction in the costs of ECG analyses for TQT studies, making cardiac safety considerations in new drug development less cumbersome. To use data generated by any proposed ECG algorithm, a quantitative and unbiased method to evaluate the reliability of such new algorithms compared with contemporary core laboratory processes is needed. Accordingly, any ECG measurement method claiming to be accurate and reliable must properly detect the positive control (moxifloxacin) effect in a TQT study.
In this document, we present results from the first use of the Cardiac Safety Research Consortium (CSRC) ECG warehouse QT/QTc testing data set, comparing IDMs obtained from a commercially available ECG algorithm applying intelligent automation (QTinno, NewCardio, Inc, Santa Clara, CA; referred to herein as developer reanalysis) blinded QT/QTc analysis to results of a contemporary core laboratory as originally submitted to the FDA on behalf of a pharmaceutical sponsor (sponsor reported). Only the moxifloxacin and placebo arms of the parallel TQT study were released by the sponsor for use by the CSRC.
Background of the CSRC ECG warehouse data
The CSRC is a public-private partnership formed within the Critical Path Initiative to advance scientific knowledge on cardiac safety issues pertinent to new drug and device development. 9 In collaboration with the FDA and the Duke Clinical Research Institute, the CSRC maintains a centralized ECG repository (the ECG warehouse) for digital ECG recordings from TQT and related studies submitted to the FDA during drug development and postmarket surveillance by industry sponsors and released to CSRC. Pharmaceutical company sponsors, who retain ownership of the recordings, have made a number of ECG warehouse data sets available to investigators, equipment manufacturers, and algorithm developers, for CSRC-approved research and development studies.
Most ECG warehouse data are waveforms collected from TQT studies performed in healthy volunteers during early phases of new drug evaluation. Cardiac Safety Research Consortium ECG data sets are composed of anonymized digital XML waveforms and key descriptive data from baseline, placebo, and moxifloxacin periods of TQT studies. The CSRC ECG warehouse supports the public domain use of these data sets for CSRC-approved research. Such research includes the testing ECG algorithms applicable to FDA cardiac safety interests such as detection of QT changes associated with moxifloxacin compared with placebo.
To meet the needs for reliable and unbiased assessment of novel ECG analysis algorithms, the CSRC has partitioned sets of ECG waveforms released with descriptor data such as treatment assignment ("unblended" or "training" data) and sets of ECG waveforms without such descriptors ("blinded" or "testing" data) for publicdomain research use. This partitioning allows developers to refine algorithms using CSRC training data, while reserving testing data for more rigorous, reportable performance testing. The testing ECG database (XML waveforms only) is provided to algorithm developers under strict predefined conditions to assure unbiased, accurate, and reliable assessment of the algorithm. These conditions include full blinding with respect to the administration of pharmaceutical agents, an independent analysis of the algorithm developer's IDMs by a CSRCaffiliated statistician, and an agreement by the developer that the results will be made public regardless of the outcome. 10 
Methods

Study design
The testing data set used for validating algorithm performance was a positive-and placebo-controlled parallel design TQT study (referred to as CSRC Study 5). Data included 11,925 anonymized digital ECG waveforms from 181 subjects, 90 of which were randomized to the positive-control arm and 91 to the placebo arm. Positive-control subjects received 400 mg oral moxifloxacin, which has been shown to prolong the QTc interval by approximately 10 ms while being adequately safe to use a single dose in studies of normal volunteers.
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All subjects had three 12-lead digital ECGs obtained within 1 to 3 minutes (providing 3 ECGs for each time point) on day 1 (baseline) and then on day 1 (treatment) at the following time points relative to placebo or moxifloxacin administration: predose (15 min) and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours postdose. The time-matched ECGs obtained on day 1 provided the baseline values. A total of 11,925 ECGs were originally submitted by the sponsor to the ECG warehouse and then subsequently reanalyzed by the developer. Of these ECGs, 241 (2.1%) were incomplete (2.5 seconds of recorded ECG data per lead compared with 10 seconds expected) and were not evaluable by the ECG algorithm (QTinno, NewCardio, Inc, Santa Clara, CA); 11 ECG files were rejected by the intelligent automation of the ECG algorithm because of high noise content; and no data were reported by the sponsor for one XML file. Thus, a total of 11,672 ECGs were available for the comparative analysis.
The virtually automated ECG reanalysis of the XML waveforms was made using QTinno, an ECG analysis algorithm that applies intelligent automation, which has been previously described. 12 Briefly, the QTinno algorithm uses the full 12-lead ECG input to generate a vector magnitude lead and then uses the vector magnitude lead for all IDMs. Fiducial point placements are made primarily by curve fitting to a thirdorder polynomial, an approach that was chosen because it is relatively noise resistant and does not require location of an isoelectric baseline. The intelligent automation of the QTinno algorithm separates those ECG readings that do not require adjudication by a human from those that are suggested for adjudication. Sixty-seven (0.57%) of the available 11,672 ECG files were flagged by the algorithm for expert cardiologist visual adjudication because of high noise content such as cardiac intervals outside the reference range, marked sinus arrhythmia, and other outlier factors. Of the 67 flagged files, 24 required adjustments by the cardiologist reader, 0.21% of the overall number of files, whereas 43 of the flagged files (0.37%) were accepted by the reader without change.
Statistical methods
The time-matched change from baseline of the following continuous ECG interval parameters was summarized at each time point on treatment day 1 during both the placebo and moxifloxacin treatment periods using central tendency analyses: QT, QTcB (Bazett's heart rate QT correction), QTcF (Fridericia's heart rate QT correction), RR, PR, and QRS. The actual QT values at each time point between sponsor-reported core laboratory and developer reanalysis measurements were not directly compared because no absolute independent gold standard exists for individual waveform measurements. Rather, using analytical comparison standards set by CSRC, differences in test performance were assessed by the ability of each method to identify a moxifloxacin effect compared with placebo by intrinsic variability within the methods and by the ability of the methods to identify a drug effect in randomly selected simulations of smaller subsets within the overall population, as described below.
Three replicate measurements were available for each interval at each time point and were averaged for each subject, denoted as the mean interval value. For each subject and time point, the change from baseline value was derived using the mean interval value on day 1 subtracted from the time-matched mean value on treatment day 1. All data analyses were generated using SAS software, Version 9 (SAS Institute Inc, Cary, NC).
Bland-Altman plots of developer reanalysis and sponsorreported core laboratory changes from baseline were reviewed for each interval (dQT, dQTcB, dQTcF, dRR, dPR, and dQRS) to evaluate unexpected differences or patterns, whereas time trend plots of the 2-sided 90% confidence intervals (CIs) of the mean value at each time point were used to review similarity/overlap of each analysis method. The average difference between developer and sponsor-reported core laboratory change from baseline values, as well as SD of the differences, was computed to observe expected CIs approximately 0 ms.
The within-subject variability of each interval was compared using the SD of the triplicate measurements at each time point Lower (LCL) and upper (UCL) 90% CI limits for the mean SD are given along corresponding P value for testing the null hypothesis of no difference between analysis methods.
averaged across the whole time course for each subject. A paired t test was used to test the null hypothesis that the mean developer SD was the same as the mean sponsor-reported core laboratory SD for each interval. P ≤ .05 was considered statistically significant. Detection of the expected baseline-and placebo-adjusted moxifloxacin prolongation of the QTcF interval (ddQTcF) was evaluated using time trend plots of the raw mean differences and 90% CIs at each local time point for each analysis method. To determine assay sensitivity while maintaining the overall 2-sided significance level (α = .10), Bonferroni multiple testing adjustment of the first 4 postdose time points (α = .025) was used. If one of the adjusted lower bounds of the 90% CIs during the first 4 hours postdose was greater than 5 ms, it would be concluded that the analysis method is sensitive to detecting small drug effects on cardiac repolarization.
The variability in the change from baseline for QTcF (dQTcF), as described by the between-subject and within-subject SDs, was estimated by fitting a mixed analysis of covariance (ANCOVA) model for each analysis method. 13 The normal mixed model for each dQTcF-dependent variable is given by
where X is the matrix of fixed effects and Z is the matrix of random effects. Subject is the random effect, whereas baseline QTcF, time point, treatment group, and time by treatment interaction are the fixed effects. We assumed a compound symmetry variance structure with equal variances across both treatment groups, because this is the most common variance structure for these data type, and tested this assumption using likelihood ratio tests comparing models using other possible covariance structures. Although not presented in this article, the 2-sided 90% CIs for ddQTcF based on the mixed ANCOVA model The between-and within-subject SDs are given for each interval and measurement method.
were constructed using the residual error to confirm results similar to raw mean results. The theoretical statistical power was estimated by bootstrap simulations on randomly selected subject groups ranging in size from 10 to 50 to observe the average maximum effect, the average within-and between-subject variances, and the number of times that assay sensitivity was detected (power) in smaller sample sizes. Assay sensitivity was determined using the Bonferroni-adjusted lower 90% CI of first 4 postdose time points. The power curves show the minimum theoretical number of subjects that would be required to achieve at least 80% power for each analysis method. Statistical power was also computed for each method considering only the betweensubject SDs of the original study design and assuming a 2-sided significance level of .10 (adjusted for 4 time points) with a true mean difference of 12 ms. 14 
Results
Table I presents summary data from Bland-Altman comparisons of sponsor-reported and developer reanalysis for baseline-adjusted changes in each interval including dQT, dRR, dQTcB, dQTcF, dPR, and dQRS intervals. The measurement methods were similar with regard to change from baseline, with an absolute mean difference b1 ms for each interval. Figure 1 displays the Bland-Altman plot for dQTcF and shows expected scatter around the mean difference (−0.35 ms) with most points lying within 2 SDs of the mean.
The average within-subject SD across all subjects and time points and by treatment group is presented in Table II for QTcF. A paired t test rejected the null hypothesis that the sponsor-reported core laboratory and developer reanalysis SDs are the same for QTcF (P b .0001). Similar comparisons were done for each IDM and yielded similar results.
Hourly changes in baseline-and placebo-adjusted QTcF intervals (ddQTcF) in sponsor-reported core laboratory and developer reanalysis data are presented in Table III and Figure 2 . Average values for mean ddQTcF were similar (7.27 and 6.98 ms, respectively), as were hourly point estimates throughout the time course of the study. Seven of the 11 hourly point estimates for mean ddQTcF were within 1 ms of each other, and CIs overlapped at all time points. In both methods, at least 3 Bonferroniadjusted lower 90% CI limits excluded 5 ms demonstrating assay sensitivity. Average standard errors were 16.7% larger for core laboratory data than for developer data (1.56 and 1.30 ms, respectively). Table IV shows the relative variability of the sponsorreported core laboratory and developer reanalysis data based on the ANCOVA model for baseline-adjusted change in each interval. The between-subject SDs for dQTcF were similar (12.94 ms for core laboratory and 12.07 ms for developer data), whereas within-subject SDs were approximately 17% larger for core laboratory relative to developer data (7.25 and 6.07 ms, respectively). Although not shown, similar differences were observed when the moxifloxacin and placebo groups were evaluated separately. For other intervals, the between-subject variances were similar, whereas the within-subject variances were modestly lower for developer than for core laboratory data.
Sponsor-reported core laboratory and developer reanalysis data were also compared for theoretical statistical power using bootstrap simulations in Table V using sample sizes varying from 10 to 80. In these simulations, both the average between-and within-subject SDs were modestly lower for developer data than for core laboratory data; however, the average peak moxifloxacin effect was higher in the core laboratory data. Nonetheless, average between-subject SD in the developer data translated into a 2.1% increase in conditional power for assay sensitivity. Considering the between-subject SDs of the original study design in Figure 3 , 65 subjects per treatment group would be required based on the core laboratory analyses versus 57 per treatment group using the developer analytic method to detect assay sensitivity with at least 80% power in a similar parallel study design providing a 12% reduction in sample size.
Discussion
This study was undertaken by the developer using the CSRC digital ECG warehouse QT data sets to perform a blinded, prospective evaluation of a novel ECG measurement technology compared with core laboratory data submitted to the US FDA by the pharmaceutical sponsor. All developer interval measurements were made blinded to treatment or other descriptors including temporal sequence. All processes for matching developer interval measurements to clinical descriptors and statistical methods for comparing assay sensitivity and variability between methods were developed and executed by CSRC independently of the developer.
Results obtained with the virtually automated developer ECG algorithm in the present study were similar to the sponsor-reported core laboratory data, both by BlandAltman analysis of baseline-adjusted change in QT, QTcB, QTcF, PR, and QRS intervals and for hourly changes in ddQTcF. These findings indicate the use of blinded testing data sets provided in the public domain through the agencies of the CSRC digital ECG warehouse. Such use includes the unbiased evaluation and comparison of new ECG technologies promoting better or more efficient quantification of QT safety concerns in earlyphase drug development.
Moreover, hourly ddQTcF results from both measurement methods correlated well with average ddQTcF values recently published by Yan et al. 15 Using a mixedmodel statistical approach, Yan et al reported that the average peak ddQTcF from 6 parallel-group studies was 11.3 ms (90% CI, 9.3-13.2 ms), occurring 4 hours after a single oral dose of moxifloxacin 400 mg. In comparison, using a mixed-model, approach the peak ddQTcF in our study was 12.79 ms (90% CI, 9.13-16.45 ms) occurring at 2 hours for sponsor-reported data, and 12.48 ms (90% CI, 9.15-15.81 ms) occurring at 4 hours for developer data.
Although mean values for measured cardiac intervals and ddQTcF were similar between sponsor-reported core laboratory and developer reanalysis data, the developer had significantly lower measurement variability than the corresponding core laboratory data. In early-phase clinical drug studies, reducing measurement variability is important for several reasons. For example, a drug that prolongs the QT interval is identified as having a QT liability if at any study time point, the 90% upper confidence limit of ddQTcF is ≥10 ms. This raises the possibility of a false-positive result if the drug does not, in fact, significantly prolong QT, but the CIs are wide because of measurement variability. Similarly, substantial measurement variability may result in a failure to detect the expected moxifloxacin effect (assay sensitivity) with at least 1 time point at which the 90% lower confidence limit excludes 5 ms.
In multiple ascending dose and other early-phase trials, lower measurement variability may also improve pharmacokinetic/pharmacodynamic correlations and improve study design for TQT and subsequent studies by providing better estimates of a drug's likely QT effect in smaller sample sizes.
In bootstrap simulations, the lower between-subject variability observed with developer data did not translate into a significantly higher theoretical study power. Although the developer data had 7% lower average between-subject SDs (which would favor higher power in bootstrap simulations), the sponsor-reported core laboratory data had approximately a 5% higher peak ddQTcF value. Because theoretical study power represents the proportion of simulations where the 90% lower confidence limit of ddQTcF excluded 5 ms at least once during the first 4 hours postdose, the higher core laboratory peak ddQTcF value made this event more likely and largely offset the difference in between-subject Power and sample size estimates for determining assay sensitivity. Assuming 4 time points postdose evaluated with overall 1-sided significance level of .05 and true mean effect of 12 ms. Sponsorreported and developer reanalysis data were presented using estimated variance from original study.
SDs. Sample size considerations of TQT studies are primarily driven by the baseline-and placebo-adjusted experimental drug comparisons. However, if we consider only the between-subject SDs of the original study design, approximately 12% fewer subjects per treatment group would be required to detect assay sensitivity based on the developer reanalysis data.
Summary
There is not a criterion standard for direct comparisons of QT IDMs, and hence, the CSRC does not report such comparison between core laboratory and new algorithms under testing. In this study, both core laboratory and developer algorithms identify similar time-and magnituderelated changes in baseline-and placebo-adjusted QT/QTc response to moxifloxacin. Thus, QTinno appears to be a reasonable and efficient alternative to the semiautomated methods used by core laboratories traditionally selected by pharmaceutical sponsors for TQT studies.
Interpretation of the implications of these findings may vary depending on the specifics of actual practical or regulatory applications. Thus, the methodologies used in this study may be useful for such considerations with these and other future ECG technology evaluations; however, the findings from these evaluations should not be construed as specific endorsement of the algorithm used in this study by either the CSRC or the FDA.
